T Cell Membrane-Anchored Tumor-Targeted IL12 -Modified TIL Cell Therapy (attIL12-TIL) for Sarcoma
This study is testing a new immunotherapy called T Cell Membrane-Anchored Tumor-Targeted IL12 -Modified TIL Cell Therapy (attIL12-TIL) along with cyclophosphamide for people with advanced or metastatic soft tissue and bone sarcoma. This means the cancer has spread or come back. The main goal is to find a safe dose of attIL12-TIL and see how well it works, especially for a type of cancer called liposarcoma. You might be able to join if you are 12 years or older and have a confirmed diagnosis of advanced or metastatic soft tissue or bone sarcoma that needs a biopsy or surgery. The study is looking at how safe the treatment is and if it can help control cancer growth.
- Study design
- This is an interventional study planning to enroll 40 participants. It is designed to find a safe dose and then test its effectiveness.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Safety and side effects will be measured throughout the study, which is expected to be an average of 1 year.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
T Cell Membrane-Anchored Tumor-Targeted IL12 -Modified TIL Cell Therapy (attIL12-TIL) for Advanced/Metastatic Soft Tissue and Bone Sarcoma Patients.
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Neeta Somaiah, MBBS · PRINCIPAL_INVESTIGATOR · M.D. Anderson Cancer Center
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Safety and adverse events (AEs)Through study completion; an average of 1 year
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0